RT Journal Article
SR Electronic
T1 An emergent, high-fatality lung disease in systemic juvenile arthritis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19002923
DO 10.1101/19002923
A1 Saper, Vivian E.
A1 Chen, Guangbo
A1 Deutsch, Gail H.
A1 Guillerman, R Paul.
A1 Birgmeier, Johannes
A1 Jagadeesh, Karthik
A1 Canna, Scott
A1 Schulert, Grant
A1 Deterding, Robin
A1 Xu, Jianpeng
A1 Leung, Ann N.
A1 Bouzoubaa, Layla
A1 Abulaban, Khalid
A1 Baszis, Kevin
A1 Behrens, Edward M.
A1 Birmingham, James
A1 Casey, Alicia
A1 Cidon, Michal
A1 Cron, Randy
A1 De, Aliva
A1 De Benedetti, Fabrizio
A1 Ferguson, Ian
A1 Fishman, Martha P.
A1 Goodman, Steven I.
A1 Graham, Brent
A1 Grom, Alexei
A1 Haines, Kathleen
A1 Hazen, Melissa
A1 Henderson, Lauren A.
A1 Ho, Assunta
A1 Ibarra, Maria
A1 Inman, CJ
A1 Jerath, Rita
A1 Khawaja, Khulood Walid
A1 Kingsbury, Daniel J
A1 Klein-Gitelman, Marisa
A1 Lai, Khan
A1 Lapidus, Sivia
A1 Lin, Clara
A1 Lin, Jenny
A1 Liptzin, Deborah R.
A1 Milojevic, Diana
A1 Mombourquette, Joy
A1 Onel, Karen
A1 Ozen, Seza
A1 Perez, Maria
A1 Phillippi, Kathryn
A1 Prahalad, Sampath
A1 Radhakrishna, Suhas
A1 Reinhardt, Adam
A1 Riskalla, Mona
A1 Rosenwasser, Natalie
A1 Roth, Johannes
A1 Schneider, Rayfel
A1 Schonenberg-Meinema, Dieneke
A1 Shenoi, Susan
A1 Smith, Judith A
A1 Sonmez, Hafize Emine
A1 Stoll, Matthew L.
A1 Towe, Christopher
A1 Vargas, Sara O.
A1 Vehe, Richard K
A1 Young, Lisa R.
A1 Yang, Jacqueline
A1 Desai, Tushar
A1 Balise, Raymond
A1 Lu, Ying
A1 Tian, Lu
A1 Bejerano, Gil
A1 Davis, Mark M.
A1 Khatri, Purvesh
A1 Mellins, Elizabeth D.
A1 ,
YR 2019
UL http://medrxiv.org/content/early/2019/08/20/19002923.abstract
AB Objective To investigate characteristics and risk factors of a novel parenchymal lung disease, increasingly detected in systemic juvenile idiopathic arthritis (sJIA).Methods In a multi-center retrospective study, 61 cases were investigated, using physician-reported clinical information and centralized analyses of radiologic, pathologic and genetic data.Results Lung disease (LD) was associated with distinctive features, including acute erythematous clubbing and a high frequency of anaphylactic reactions to the IL-6 inhibitor, tocilizumab. Serum ferritin elevation and/or significant lymphopenia preceded LD detection. The most prevalent chest CT pattern was septal thickening, involving the periphery of multiple lobes +/- ground glass opacities. Predominant pathology (23/36) was pulmonary alveolar proteinosis and/or endogenous lipoid pneumonia (PAP/ELP), with atypical features, including regional involvement and concomitant vascular changes. Apparent severe delayed drug hypersensitivity occurred in some cases. 5-year survival was 42%. Whole-exome sequencing (20/61) did not identify a novel monogenic defect PAP-related or macrophage activation syndrome (MAS)-related mutations as likely primary cause. Trisomy 21 (T21) increased LD risk, as did young sJIA onset. Refractory sJIA was not required for LD development. Exposure to interleukin (IL)-1 and IL-6 inhibitors (46/61) was associated with multiple LD features. By several indicators, severity of sJIA was comparable in drug-exposed subjects and published sJIA cohorts. MAS at sJIA onset was increased in the drug-exposed, but it was not associated with LD features.Conclusions A rare, life-threatening LD in sJIA is defined by a constellation of unusual clinical characteristics. The pathology, a PAP/ELP variant, suggests macrophage dysfunction. Inhibitor exposure may promote LD, independent of sJIA severity, in a small subset of treated patients. Treatment/prevention strategies are needed.Competing Interest StatementAll the following competing interests are outside the submitted work. Dr. Mellins reports a research grant from Novartis. Dr. Shenoi reports personal fees from Novartis. Dr. Canna reports personal fees from Novartis, grants from AB2Bio, Ltd. Dr. Stoll reports personal fees from Novartis. Dr. Grom reports grants and personal fees from Novartis, grants from NovImmune.Dr. Deutsch reports personal fees from Novartis.Dr. Saper reports personal fees from Novartis.Dr. Schneider reports personal fees from Novartis, Novimmune and SOBI; Dr. Young reports other from Up To Date, other from Boehringer Ingelheim; Dr. Baszis reports personal fees from Novartis. Funding StatementThis work was supported by the sJIA Foundation (EDM), the Lucile Packard Foundation for Children's Health (EDM), CARRA-Arthritis Foundation grant (EDM, VS), Life Sciences Research Foundation (GC), Bio-X Stanford Interdisciplinary Graduate Fellowship (JB), Stanford Graduate Fellowship and the Computational Evolutionary Human Genetics Fellowship (KJ). NIH (LRY); Bill & Melinda Gates Foundation (PK), NIH: 1U19AI109662 (PK), U19AI057229 (PK), RO1 AI125197 (PK).Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableData are available upon reasonable request.